Characteristic | V. alginolyticus | V. parahaemolyticus | V. cholerae non-O1/O139 | V. vulnificus | Other species |
---|---|---|---|---|---|
Total patients | 23 (100) | 20 (100) | 10 (100) | 7 (100) | 7 (100) |
Demographics | |||||
Age, y, median (SD) | 50 (+26.7) | 53 (+22.8) | 69 (+19.7) | 66 (+11.5) | 40 (+24.8) |
Sex | |||||
M | 19 (83) | 15 (75) | 7 (70) | 7 (100) | 6 (86) |
F | 4 (17) | 5 (25) | 3 (30) | 0 | 1 (14) |
Underlying condition | |||||
Heart failure | 8 (35) | 6 (30) | 5 (50) | 4 (57) | 1 (14) |
Neoplasia | 1 (4) | 5 (25) | 4 (40) | 0 (0) | 1 (14) |
Diabetes | 2 (9) | 3 (15) | 1 (10) | 1 (14) | 1 (14) |
Kidney failure | 2 (9) | 1 (5) | 1 (10) | 0 | 3 (43) |
Immune disease | 2 (9) | 2 (10) | 1 (10) | 0 | 2 (29) |
Hemopathy | 1 (4) | 1 (5) | 1 (10) | 1 (14) | 1 (14) |
Liver disease | 1 (4) | 1 (5) | 2 (20) | 1 (14) | 0 |
Alcohol use disorder | 2 (9) | 1 (5) | 2 (20) | 2 (29) | 0 |
Preexisting wound | 3 (13) | 0 | 0 | 3 (43) | 0 |
Digestive surgery | 2 (9) | 2 (10) | 1 (10) | 0 | 1 (14) |
Time to symptom onset, d, median (SD) | 2.4 (+2.0) | 1.3 (+0.9) | 3 (+4.4) | 5.6 (+8.1) | 1 (+0.0) |
Infection type | |||||
Acute | 14 (61) | 19 (95) | 10 (100) | 7 (100) | 5 (71) |
Chronic | 9 (39) | 1 (5) | 0 | 0 | 2 (29) |
Outcome | |||||
Recovered | 21 (91) | 17 (85) | 8 (80) | 6 (86) | 7 (100) |
Died | 2 (9) | 3 (15) | 2 (20) | 1 (14) | 0 |
Table 1. Clinical characteristics of patients with Vibrio infection, by species, Bay of Biscay, France, 2001–2019*
*Values are no. (%) except as indicated.
Antibiotic | V. alginolyticus | V. parahaemolyticus | V. cholerae non-O1/O139 | V. vulnificus | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S | I | R | S | I | R | S | I | R | S | I | R | ||||
Amoxicillin | 1 | 0 | 15 | 1 | 6 | 7 | 2 | 2 | 3 | 5 | 0 | 0 | |||
Ticarcillin | 5 | 0 | 10 | 2 | 2 | 9 | 5 | 0 | 1 | 5 | 0 | 0 | |||
First-generation cephalosporin | 10 | 4 | 0 | 13 | 1 | 0 | 4 | 1 | 0 | 4 | 1 | 0 |
Table 2. Available drug-susceptibility test results for the main antibiotics used to treat Vibrio infections, by species, Bay of Biscay, France, 2001–2019*
*Data are no. of cases. I, intermediate; R, resistant; S, susceptible.
Characteristic | No sepsis, n = 42 | Septic shock, n = 13 | p value | ||||
---|---|---|---|---|---|---|---|
No. | % (95% CI) | No. | % (95% CI) | ||||
Patient sex | |||||||
M | 35 | 83 (72–95) | 10 | 77 (54–100) | 0.685 | ||
F | 7 | 17 (5–28) | 3 | 23 (0.2–46) | |||
Underlying conditions | |||||||
Heart failure | 18 | 43 (28–58) | 6 | 46 (19–73) | Referent | ||
Neoplasia | 6 | 14 (4–25) | 4 | 31 (6–56) | 0.223 | ||
Diabetes | 7 | 17 (5–28) | 1 | 8 (0–22) | 0.664 | ||
Kidney failure | 5 | 12 (2–22) | 2 | 15 (0–35) | 0.664 | ||
Immune disease | 5 | 12 (2–22) | 2 | 15 (0–35) | 0.664 | ||
Hemopathy | 3 | 7 (0–15) | 2 | 15 (0–35) | 0.582 | ||
Liver disease | 2 | 5 (0–11) | 3 | 23 (0–46) | 0.318 | ||
Alcohol use disorder | 3 | 7 (0–15) | 4 | 31 (6–56) | 0.102 | ||
Preexisting wound | 6 | 14 (4–25) | 0 | 0 (0–0) | 0.317 | ||
Digestive surgery | 4 | 10 (1–18) | 2 | 15 (0–35) | 0.618 | ||
Species | |||||||
V. alginolyticus | 10 | 24 (11–37) | 4 | 31 (6–56) | |||
V. parahaemolyticus | 14 | 33 (19–48) | 5 | 38 (12–65) | |||
V. cholerae non-O1/O139 | 8 | 19 (7–31) | 2 | 15 (0–35) | |||
V. vulnificus | 6 | 14 (4–25) | 1 | 8 (0–22) | |||
Other Vibrio species | 4 | 10 (1–18) | 1 | 8 (0–22) | |||
Outcome | |||||||
Recovered | 40 | 95 (89–100) | 7 | 54 (27–81) | 0.001 | ||
Died | 2 | 5 (0–11) | 6 | 46 (19–73) |
Table 3. Clinical characteristics and outcome of patients with and without septic shock after acute Vibrio infection, Bay of Biscay, France, 2001–2019*
*Median patient age ( + SD) was 60 ( + 21.4) for no sepsis and 61 ( + 15.3) for septic shock.
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 1.00 ABIM MOC points
This activity is intended for primary care physicians, infectious disease specialists, and other clinicians who treat and manage patients who may become infected with Vibrio spp.
The goal of this activity is to assess the epidemiology, microbiology, and prognosis of infection with Vibrio spp.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
processing....
Data from 67 patients diagnosed with Vibrio infection were available for the period 2001–2019 (Table 1). Most patients were men (81%), and the average age was 54 years (SD +24 years). In the subgroup of patients with acute infections (including cutaneous infections and gastroenteritis), the mean age was 60 (SD +20) years, and 71% of the patients had >1 underlying condition. Patients with chronic ear infections were younger (mean age 27 years [SD +24 years]), and all but 1 had no underlying conditions.
The description of environmental factors was available for 57% of patients. Among those patients, 55.3% of infections were contracted at the beach, 39.5% by handling or eating seafood, and 5.3% while abroad. Most infections (82%) occurred during June–September. The number of reported cases reached 2 peaks, in 2003 and 2018.
The average duration between known exposure and onset of symptoms was 2.4 days (SD +3.8 days), and it varied from <1 day for patients with gastroenteritis, cellulitis, or pneumonia, to 20 days for patients with osteitis. Digestive disorders were reported in 23 (34.4%) of the patients, including 6% with severe intraabdominal infection (Table 2). Cellulitis was reported in 23 (34.4%) of the patients, and 3 had soft tissue infection complicated by osteitis. Near drowning–associated pneumonia was reported in 8 (12%) of the patients. A case of endocarditis was described in a patient whose pacemaker had been exposed to seawater through a preexisting chronic wound while swimming in the Atlantic Ocean. Chronic ear infection (chronic otitis or cholesteatoma) affected 12 (18%) of the patients.
Vibrio infections were diagnosed from blood samples (26.9%), feces (20.9%), biopsies (20.9%), ear swab samples (17.9%), bronchoalveolar lavage samples (7.5%), and skin samples (6%). The most frequently identified species were V. alginolyticus (34%) and V. parahaemolyticus (30%). V. cholerae non-O1/O139 was found in 15% of patients, and V. vulnificus was found in 10%. The remaining patients were infected with other Vibrio species. Other bacteria were co-isolated in samples from 5 patients (methicillin-sensitive Staphylococcus aureus in 2 skin samples; Streptococcus mitis in a bronchoalveolar lavage; Proteus vulgaris and Haemophilus influenza in another bronchoalveolar lavage; and Klebsiella pneumoniae, Enterococcus faecalis, and Enterobacter cloacae in a bone biopsy).
Susceptibility testing revealed strains with resistance or intermediate resistance to amoxicillin in most V. alginolyticus, V. parahaemolyticus, and V. cholerae non-O1/O139 strains (Table 2). Strains with resistance or intermediate resistance to ticarcillin were also found in most V. alginolyticus and V. parahaemolyticus strains and to a lesser extent in V. cholerae non–O1/O139 strains. V. vulnificus strains were sensitive to all of these penicillins.
V. alginolyticus was responsible for various pathologies, but more particularly for otitis (39%) (Figure).
Figure. Diseases caused by Vibrio infection in 67 patients, by species, Bay of Biscay, France, 2001–2019. A) V. alginolyticus. B) V. parahaemolyticus. C) V. cholerae non-O1/O139. D) V. vulnificus. Numbers in chart sections indicate number of patients. Intraabdominal infection corresponds to pancreatitis, liver abscess, phlegmoneous ileitis, cholecystis, and peritonitis.
V. parahaemolyticus was identified in patients with cellulitis (40%) and gastroenteritis (40%). V. cholerae non-O1/O139 was almost exclusively responsible for digestive disorders (90%). V. vulnificus was exclusively found in cellulitis and soft tissue infections complicated by osteitis.
Most (84%) patients required hospitalization. The average time from symptom onset to treatment was 2.7 days (SD +4.9) days. Most of the patients received antibiotics (90%), of whom >50% received a multidrug regimen. The main prescribed antibiotics were penicillins (91%), quinolones (36%), cephalosporins (30%), metronidazole (15%), tetracycline (10%), and aminoglycosides (9%).
Twenty-two patients (33%) underwent surgery. Eleven patients with necrotizing cellulitis and 3 patients with osteitis required surgical debridement. For 6 of those 11 patients, amputation was necessary. Five patients with chronic ear infection required either surgical excision (n = 3), meatotomy (n = 1), or tympanoplasty (n = 1). Two patients had a cholecystectomy, and 1 patient with phlegmonous ileitis had partial colectomy.
All patients with chronic infection were cured. Among patients with acute infection, 13 (24%) went into septic shock (Table 3), 6 (11%) had amputations, and 8 (14%) died. Half of the amputations were associated with V. vulnificus infections. Older age and malignant hemopathy (e.g., acute leukemia and lymphoma under chemotherapy) were associated with death. Three patients suffered pneumonia after near drowning, and death may have been attributable to cardiorespiratory arrest and intensive care complications. A probable link between Vibrio infection and death could be established for 5 patients. The case-fatality rate was the highest for V. vulnificus infections (1 attributable death out of 7 infections), followed by V. parahaemolyticus (2 attributable deaths out of 19 infections) and V. cholerae non-O1/O139 (1 attributable death out of 10 infections). The case-fatality rate was the lowest for V. alginolyticus infections (1 attributable death out of 14 infections).